Overview

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2022-03-02

Target enrollment:

Participant gender:

Summary

The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Collaborator:

Medivation, Inc.

Treatments:

Talazoparib